SAB Biotherapeutics
SABS
SABS
37 hedge funds and large institutions have $92.7M invested in SAB Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
Holders
37
Holders Change
+11
Holders Change %
+42.31%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
6
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
1 |
GCL
1
Glazer Capital LLC
New York
|
$5.31M |
2 |
KC
2
Kepos Capital
New York
|
$5.26M |
3 |
KIM
3
Karpus Investment Management
Pittsford,
New York
|
$10.3M |
4 |
BFM
4
Boothbay Fund Management
New York
|
$3.99M |
5 |
CH
5
CVI Holdings
Wilmington,
Delaware
|
$3.49M |